Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. in Business Administration in Management Information Systems from Northeastern University. Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Science from Northeastern University. Kathryn Spencer is an Executive Assistant at RA Capital Management. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. RA Capital | Team Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. (L-R) Robert Morgan, Jamie Anderson and Mark Blutman, collaborators on forthcoming 'Arigato Tokyo' Courtesy/Getty. Peter Kolchinsky Founder and CEO RA Capital Management. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Mike earned his MBA from the Darden Graduate School of Business Administration. Michael Sherman is a Venture Partner at RA Ventures. in Mechanical & Aerospace Engineering from Sharif University of Technology, Tehran, Iran and a PhD in Molecular Engineering from Pritzker School of Molecular Engineering, University of Chicago. Ramaswamy, who just turned 30, has bigger aspirations. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. Brackett Hardy is a Junior Associate with the TechAtlas division of RA Capital Management. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Henry has a BA in Biology & Economics from Dartmouth College. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. Jenna Hebert is an Associate within the TechAtlas division of RA Capital Management. He is also an active member of the Big Brothers of Massachusetts Bay program. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology fellowship at Massachusetts General Hospital / Harvard Medical School as well post-doctoral training with Frederick Alt, an HHMI investigator, in molecular immunology. He is also an Advisor to HotSpot Therapeutics and recently served on the Board of Directors at Research Alliance Corporation I (merged with POINT Biopharma) and at TetraGenetics (acquired by AbCellera). Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. From time to time we may post specific open positions, but more often we will create positions for the right people. Peter Kolchinsky was born in the United States of America. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Previously, Danielle was an Associate at RA Capital, and worked in IP and tech licensing at Seven Bridges Genomics and the MIT Technology Licensing Office, respectively. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities.
Reuben Foster High School,
Jesse Feldman Net Worth,
Short Tithes And Offering Message,
Mitch Landrieu Speech Rhetorical Analysis,
Diferencia Entre Olivo Natural Y Olivo Silvestre,
Articles P